Cytori Therapeutics, Inc. (NASDAQ: CYTX) is committed to providing patients and physicians around the world with medical technologies, which harness the potential of adult stem and regenerative cells from adipose tissue. The proprietary Cytori Cell Therapy is under evaluation in the U.S. for the treatment of patients with hand and finger involvement due to the autoimmune condition sleroderma, as well as patients with symptomatic knee osteoarthritis. This technology is approved in many countries around the world, and the company has a number of active global partnerships with academic hospitals, companies and government agencies that share its interest in bringing Cytori Cell Therapy to patients in need. For more information, visit the company’s website at www.cytori.com.